Effective lipoprotein filtration with MONET®
MONET® stands for Membrane Filtration Optimized Novel Extracorporeal Treatment.
Lipoprotein filtration with MONET® is used to reduce high molecular weight molecules such as:
- High molcular weight lipoproteins — specifically LDL-C and Lp(a)
- High molcular weight plasma proteins that are rheological relevant
The MONET® plasma fractionator contains a Fresenius Polysulfone® membrane, enhanced for use in lipoprotein filtration.
The membrane has the same excellent biocompatibilities as other Fresenius filters and is the result of our continuous product improvement procedures.
MONET® treatment procedure
During lipoprotein filtration, venovenous or AV fistula access can be used. The procedure consists of two steps: In step one, the plasma is separated from whole blood by plasma filtration or centrifugation. In step two, the plasma is passed through a second filter, the MONET® plasma fractionator. MONET® retains high-molecular components, such as:
- Low density lipoprotein (LDL)
- Very low density lipoprotein (VLDL)
- IgM and IgA
Finally, the purified plasma is combined again with the whole blood and returned to the patient.
Benefits of treatment with MONET®
- Effective reduction of LDL-C and Lp(a) levels1
- Rheological benefits result from the reduction of macromolecules, fibrinogen and immunoglobulines1, 2
- Broad range of possible indications
- Substantiated filtration procedure
Anticoagulation can be customized according to the patient’s needs
Four different anticoagulation regimes are possible:
- ACD-A, continuously throughout the treatment procedure
- Heparin, continuously throughout the treatment procedure
- ACD-A and Heparin, combined continuously throughout the treatment procedure
- Heparin manually during the treatment procedure or as an initial patient bolus prior to treatment
MONET® can be carried out with:
- Either the haemoadsorption machine Art Universal
- Or a blood cell separator / centrifuge (e.g. COM.TEC®)
1 Julius U et al.; Therapeutic Apheresis and Dialysis Apr. 2013; 17(2): 179–84.
2 Julius U et al.; Atherosclerosis Supplements May 2015; 18: 95–102